A Phase 2 interventional study of AV-001 Injection and AV-001 Placebo Injection in Acute Respiratory Distress Syndrome, Viral or Bacterial Infections and Pneumonia, sponsored by Vasomune Therapeutics, Inc.. Active, not recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Vasomune Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 112th largest by enrollment of the 250 interventional ones that give a count, is one of 27 that started in 2021, is one of 74 in phase 2, reaches primary completion later than 11 of the 55 other live ones, and was the 266th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 7 days–30 days
Ohio State University · Sites in United States
Ages 18+
University of Texas Southwestern Medical Center · Sites in United States
Ages 0 hrs–72 hrs
Massachusetts General Hospital · Sites in United States
Ages 18–80
Implicit Bioscience · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
324 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 101 · Phase 3 46 · Phase 4 6
First in 1991; this study’s year is marked. 27 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 60 across 823 interventional studies indexed under Respiratory Distress Syndrome.
Median enrollment 52 across the 250 interventional studies, 85 across the 68 observational. Of the 220 that completed or were terminated, 101 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 324 have an industry lead sponsor. The 10 most frequent:
Vasomune Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Vasomune Therapeutics, Inc. has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
20 of the studies in Respiratory Distress Syndrome with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06776783Phase 3Aerogen Pharma LimitedSafety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome | 2027-05 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05354141Phase 3Direct Biologics, LLCExtracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS) | 2027-11-30 |
| NCT04369599Emory UniversityTrans Thoracic Manipulation of Ventilation/Perfusion: the V/Q System | 2026-11 |
| NCT07674953University of ArkansasHow Different Levels of CPAP Affect Oxygen Delivery and Lung Expansion in Preterm Infants | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 324 studies in Respiratory Distress Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be recruited from up to 25 participating institutions/hospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).
Pneumonia is a leading cause of hospitalization among adults and children in the United States and has ranked among the top 10 causes of death according to the CDC. A large variety of microorganisms can cause pneumonia including respiratory viruses, bacteria and fungi and there are great geographic variations in their prevalence. In the United States, common causes of viral pneumonia are SARS-CoV-2, influenza and respiratory syncytial virus (RSV) and bacterial pneumonia are Streptococcus pneumoniae (pneumococcus).
Emerging evidence indicates that the respiratory system mechanics of patients with typical ARDS, with or without COVID-19 are broadly similar in contrast to earlier reports that suggested COVID-19-associated ARDS has distinctive features. SOC for patients with ARDS remains limited with current interventions that focus primarily on supportive therapy, including fluid management strategies and further injury prevention via lung protective ventilation. Ventilation approaches remain the cornerstone in the treatment of ARDS and approaches to minimize ventilator-induced lung injury (VILI) resulting from the imposition of stretch-trauma to the lung, continue to be a major focus of clinical importance. Several techniques may be utilized to accomplish this objective. Clinical guidelines strongly recommend volume-limited or pressure-limited ventilator approaches for patients with severe ARDS and high positive-end expiratory pressure strategies for patients with moderate to severe ARDS. Despite decades of improving supportive care, mortality remains high, ranging from 34.9% of patients with mild ARDS to 46.1% of patients with severe ARDS.
Whatever the causative organism it is increasingly apparent that their impact on lung microvasculature is a major contributing factor to morbidity and mortality associated with those infections. Most deaths from influenza virus infections occur due to pulmonary complications, in particular the development of acute respiratory distress syndrome (ARDS), that is due to increased permeability of the lung microvasculature. Emerging evidence in COVID-19 infections suggest a similar pathophysiology where pulmonary endothelial cells and vascular dysfunction contribute to the initiation and propagation of ARDS by altering blood vessel integrity, promoting a pro-coagulative state, inducing endotheliitis and mediating inflammatory cell infiltration. Therefore, a therapeutic intervention that could modulate the course of pulmonary disease not by treating the causative organism but by reducing the deleterious inflammatory sequalae of those infections may have a significant positive impact
AV-001 is a synthetic Angiopoietin-1 (Angpt-1) mimetic that has been shown to activate the Tie2 receptor tyrosine kinase; a transmembrane protein target most highly expressed on the surface of endothelial cells in the vasculature. The Tie2/Angiopoietin signaling axis has been identified as a nonredundant gatekeeper of vascular homeostasis. In healthy individuals, Tie2 is highly activated and signals the endothelium to fortify intracellular junctions and reduce expression of adhesion molecules, which serve as leukocyte tethers upon inflammation. As such, homeostatic activation results in the promotion of barrier defense against vascular leakage.
A total of 60 eligible patients (20 patients each in cohorts 1, 2 and 3) will be recruited from participating institutions / hospitals. Patients will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with SOC. All patients will receive supportive care according to the SOC for the trial site hospital likely to include remdesivir and or dexamethasone. Study drug will be administered by bolus IV injection (\< 60 seconds). Doses of AV-001 Injection to be administered will start with the lowest proposed dose of 12.5 μg/kg/day in cohort 1 (DL1) and are anticipated to increase to 25μg/kg/day in cohort 2 (DL2), 56 μg/kg/day in cohort 3 (DL3).
The study population for this Phase 2a study will consist of male and non-pregnant female patients, ≥ 18 years of age, hospitalized with presumed pneumonia secondary to SARS-CoV-2 or other viral or bacterial infection with acute onset to a respiratory compromise requiring supplemental oxygen therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Signs and symptoms:
At least 1 of the following signs:
AND at least 1 of the following symptoms:
Rales or bronchial breath sounds;
Exclusion Criteria:
Any concurrent serious medical condition or concomitant medication that would preclude participation in the study including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC). Doses of AV-001 Injection will start with 12.5 μg/kg/day in cohort 1 and are anticipated to increase to 25 μg/kg/day in cohort 2, 56 μg/kg/day in cohort 3.
Drug: AV-001 Injection
A total of 60 eligible patients (20 patients in each of cohort 1, 2 and 3) will be randomized in a 1:1 ratio to receive either AV-001 Injection or AV-001 placebo Injection, together with standard of care (SOC).
Drug: AV-001 Placebo Injection
AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
D-PBS
Safety and tolerability of multiple doses of IV administrations of AV-001 Injection compared with AV-001 placebo Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections.
* Number of patients with any serious adverse event (SAE) (day 1 to 60/EOS) * Number of patients with any treatment emergent adverse event (TEAE) (day 1 to 60/EOS) AE assessments (day 1 to 60/EOS)
Time frame: Up to Day 60
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as proportion of patients achieving a 2-point improvement in WHO COVID-19 CPS score from baseline and alive by day 28.
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Time to first 2-point WHO CPS improvement using a Kaplan-Meier lifetable
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as survival at day 28, displayed with a Kaplan- Meier lifetable.
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as proportion of patients that progress to respiratory failure by day 28.
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as proportion of patients that progress to mechanical ventilation by day 28.
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as proportion of patients with disease improvement of at least 1 point on the WHO COVID-19 CPS for 3 consecutive days and sustained the improvement through day 28.
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
SpO2 saturation (up to day 28): measured as proportion of patients achieving normalization (last oxygen saturation of arterial blood \[SaO2\] value \> 95%).
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections.
Oxygen delivery: measured as the product of flow rate and volume per day.
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections.
Measured as the acute kidney injury stage distribution over time using the Kidney Disease Improving Global Outcomes (KDIGO) definition of Acute Kidney Injury (AKI).
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as proportion of patients alive and discharged from the intensive care unit (ICU) at day 28.
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as proportion of patients alive and discharged from hospital at day 28.
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as time to hospital discharge status (discharge or day 28, whichever is earlier).
Time frame: Up to Day 28
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as alive at day 60, displayed with a Kaplan- Meier lifetable.
Time frame: Up to Day 60
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as proportion of patients that progress to respiratory failure by day 14.
Time frame: Up to Day 14
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as proportion of patients that progress to mechanical ventilation by day 14.
Time frame: Up to Day 14
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Proportion of patients achieving a 2-point improvement in WHO COVID-19 CPS score from baseline and alive by day 14.
Time frame: Up to Day 14
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as proportion of patients alive and discharged from the intensive care unit (ICU) at day 14.
Time frame: Up to Day 14
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as proportion of patients alive and discharged from hospital at day 14.
Time frame: Up to Day 14
Efficacy of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection in patients hospitalized with pneumonia due to COVID-19 and/or other respiratory infections
Measured as durable loss of eGFR (by day 28 and day 60) from baseline (89-60 mL/min, 59-45 mL/min, 30-44 mL/min, \<30 mL/min) or the development of severe AKI requiring continuous renal replacement therapy (CRRT), prolonged intermittent renal replacement therapy (PIRRT) or hemodialysis.
Time frame: Up to Day 60
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on exploratory biomarkers of Tie2 target engagement
Measured as ratio of phosphorylated Tie2/Total Tie2 using flow cytometry analysis.
Time frame: Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on exploratory biomarkers (Angpt-1, Angpt-2, and circulating Tie2).
Measured using quantitative ELISA.
Time frame: Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarkers IL-6 in patients with pneumonia due to COVID-19 and/or other respiratory infections.
Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Time frame: Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarker IL-8 in patients with pneumonia due to COVID-19 and/or other respiratory infections.
Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Time frame: Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarkers TNFr-1 in patients with pneumonia due to COVID-19 and/or other respiratory infections.
Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Time frame: Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarker MCP-1 in patients with pneumonia due to COVID-19 and/or other respiratory infections.
Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Time frame: Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarker IP-10 in patients with pneumonia due to COVID-19 and/or other respiratory infections.
Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Time frame: Up to Day 28
Effect of multiple IV administrations of AV-001 Injection compared with AV-001 placebo Injection on disease biomarker ICAM-1, in in patients with pneumonia due to COVID-19 and/or other respiratory infections.
Measured at screening and at pre-dose on days 2, 4, 7, 10, 13, 16, 19, 22, 25 and the earlier of day 28 or EOT using quantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Time frame: Up to Day 28
PK as measured by Cmax of AV-001 Injection in hospitalized patients with severe COVID-19 disease.
Assessment of the PK of AV-001 Injection in hospitalized patients with severe COVID-19 disease using population PK for DL1, DL2 and DL3. PK measured as Cmax from sample timepoints Pre-dose, 5 min, 30 min, 1, 2, 4, and 24 hours post-dose on days 1, 7 and the earlier of day 28 or EOT.
Time frame: Up to Day 28
PK as measured by Tmax of AV-001 Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections.
Assessment of the PK of AV-001 Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections using population PK for DL1, DL2 and DL3. PK measured as Tmax, from sample timepoints Pre-dose, 5 min, 30 min, 1, 2, 4, and 24 hours post-dose on days 1, 7 and the earlier of day 28 or EOT.
Time frame: Up to Day 28
PK as measured by AUC of AV-001 Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections.
Assessment of the PK of AV-001 Injection in hospitalized patients with pneumonia due to COVID-19 and/or other respiratory infections using population PK for DL1, DL2 and DL3. PK measured as AUC from sample timepoints Pre-dose, 5 min, 30 min, 1, 2, 4, and 24 hours post-dose on days 1, 7 and the earlier of day 28 or EOT.
Time frame: Up to Day 28
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Sep 2026, 57 months after the start.
Of 59 phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 57 months is above that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion May 2026 → Sep 2026 and completion Jun 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
Vasomune Therapeutics, Inc.